GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » 3-Year EPS without NRI Growth Rate

Sensei Biotherapeutics (HAM:407) 3-Year EPS without NRI Growth Rate : -20.60% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics 3-Year EPS without NRI Growth Rate?

Sensei Biotherapeutics's EPS without NRI for the three months ended in Mar. 2024 was €-0.29.

During the past 3 years, the average EPS without NRI Growth Rate was -20.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 32.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Sensei Biotherapeutics was 62.00% per year. The lowest was -20.60% per year. And the median was -9.80% per year.


Competitive Comparison of Sensei Biotherapeutics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Sensei Biotherapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's 3-Year EPS without NRI Growth Rate falls into.



Sensei Biotherapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Sensei Biotherapeutics  (HAM:407) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Sensei Biotherapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics (HAM:407) Business Description

Industry
Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics (HAM:407) Headlines

No Headlines